HUBEI PROVINCE, China, May 13 /Xinhua-PRNewswire/ -- Benda Pharmaceutical, Inc. (OTC Bulletin Board: BPMA), a China-based pharmaceutical company producing both Gendicine(R), a commercialized gene therapy medicine for the treatment of cancer, and traditional Chinese and conventional medicines, today announced that its subsidiary, Jiangling Benda Pharmaceutical Co., Ltd. ("Jiangling Benda"), has received the Good Manufacturing Practice ("GMP") certificate by the Chinese State Food and Drug Administration ("SFDA") authorizing the production of Ribavrin at its Jiangling Plant.
"We are very excited that our Jiangling plant has successfully obtained the GMP certificate. This certificate represents the endorsement of our quality control system and production facilities by the SFDA, and is a major step to launch and market our Ribavrin in the domestic market," stated Charles Wan, Chief Executive Officer of Benda Pharmaceutical.
Jiangling Benda plans to produce four types of Active Pharmaceutical Ingredients (APIs), including Ribavrin, Asarin, Levofloxacin Mesylate and Ribose. The production of the APIs, with the exception of Ribose, requires GMP certification. The Jiangling plant was closed for renovation in July 2004 to comply with GMP standards and was reopened in August 2007 for the production of Ribose. It currently has all of the production equipment in place, and the new facilities have been installed and tested for Ribavrin and Ribose.
Additional information regarding this certificate, issued on April 9, 2008, can be found on the SFDA website ( http://www.sfda.gov.cn ).
About Jiangling Benda
Jiangling Benda develops, manufactures and sells Active Pharmaceutical Ingredients ("APIs"), which are one of the two components of any capsules, tablets and fluids that are pharmaceutically active. An API is the substance in a drug that produces the desired medicinal effect. The "excipient" is the inert material that holds the API (such as gelatin or water). About 3.7 per cent of the APIs that Jiangling Benda produced in 2004 were used to produce some of the company's finished medicines. The remainder was sold in the market to unrelated parties. Jiangling Benda did not sell to related Benda companies in 2006 or 2007.
About Benda Pharmaceutical, Inc.
Benda Pharmaceutical, Inc. ( http://www.bendapharma.com ), a China-based pharmaceutical company, produces traditional Chinese and conventional medicines, as well as Gendicine(R), a commercialized gene therapy medicine for the treatment of cancer.
Safe Harbor Statement
The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.